drugset / Trial / NCT03643510
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effectiveness of the combination of abemaciclib and fulvestrant in treating this type of cancer and to determine the types and severity of side effects caused by treatment with abemaciclib and fulvestrant.
Timeline
- Start
- 2018-08-21
- Primary completion
- 2026-03-12
- Completion
- 2026-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |